ABL Bio Inks US$1.06 bln Deal with Sanofi for Parkinson's Disease Treatment | Be Korea-savvy

ABL Bio Inks US$1.06 bln Deal with Sanofi for Parkinson’s Disease Treatment

This photo provided by ABL Bio Inc. shows the company's headquarters in Pangyo, east of Seoul.

This photo provided by ABL Bio Inc. shows the company’s headquarters in Pangyo, east of Seoul.

SEOUL, Jan. 12 (Korea Bizwire)South Korea’s biotech company ABL Bio Inc. said Wednesday it has entered a global license agreement worth US$1.06 billion with pharmaceutical giant Sanofi to develop and commercialize an antibody candidate to treat Parkinson’s disease.

ABL301 is a preclinical antibody therapeutic under development as a potential treatment of synucleinopathy, including Parkinson’s disease.

Under the agreement, ABL will receive $75 million in upfront payments and is eligible to receive up to $985 million based on the achievement of commercialization milestones, including $45 million in near-term milestones.

ABL is also eligible to receive royalties on net sales if the product from the collaboration is commercialized, the South Korean firm said.

In return, the France-based drug giant will receive global exclusive development and commercialization rights to ABL301, according to ABL.

ABL said it will lead the preclinical development and phase one clinical trial of ABL301, while Sanofi will be responsible for further clinical development, regulatory approval and global commercialization.

ABL301 is developed based on using ABL’s Grabody-B platform technology to maximize blood-brain barrier (BBB) penetration. ABL301 effectively carries the anti-alpha-synuclein antibody across the BBB to enhance therapeutic efficacy against Parkinson’s disease.

“This groundbreaking partnership with Sanofi proves the immense possibilities of ABL’s innovative antibody technology,” ABL Bio CEO Lee Sang-hoon said in a press release.

“We will continue to develop our Grabody-B platform and expand its applicability in other neurodegenerative diseases, such as Alzheimer’s.”


One thought on “ABL Bio Inks US$1.06 bln Deal with Sanofi for Parkinson’s Disease Treatment

  1. Leslie Bartnicki

    The love of my life for 15 years was diagnosed 2 years ago at age 54. Symptoms were tremor in right leg, loss of handwriting ability, and soft voice. He also have difficulty rising from a seated position and have balance issues. he started out taking only Azilect, then Mirapex, and 6 months ago Sinemet. Several months ago he started falling frequently, hence the reason for Sinemet. We tried every shots available but nothing worked. In March 2023, my neurologist and I decided to go with natural treatment and was introduced to Natural Herbs Centre Ayurvedic organic Parkinson’s protocol, he had a total decline of symptoms with this treatment, the Tremor, falling frequently, stiffness, body weakness, balance issues, depression and others has subsided. Visit Natural Herbs Centre official website naturalherbscentre. com. This treatment is a breakthrough for all suffering from Parkinson’s, don’t give up Hope. Keep Sharing the Awareness, herbs are truly gift from God. I can personally vouch for these remedy but you would probably need to decide what works best for you


Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>